GB1219606A — Quinuclidinol derivatives and preparation thereof
Assigned to RECH S ET D APPLIC SCIENT SOGE · Expires 1971-01-20 · 55y expired
What this patent protects
1,219,606. Esters of 3-quinuclidinol. SOC. GENERALE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SOGERAS). 14 July, 1969 [15 July, 1968], No. 33654/68. Heading C2C. The invention comprises compounds of formula wherein R is H, OH or C 1-4 alkyl, R 1 is Ph or thienyl, and R 2 …
USPTO Abstract
1,219,606. Esters of 3-quinuclidinol. SOC. GENERALE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SOGERAS). 14 July, 1969 [15 July, 1968], No. 33654/68. Heading C2C. The invention comprises compounds of formula wherein R is H, OH or C 1-4 alkyl, R 1 is Ph or thienyl, and R 2 is cyclohexyl, cyclopentyl or thienyl, or when R is H, R 1 R 2 C froms a 9-(9,10) dihydroanthryl, 9-xanthyl or 9-thioxanthyl group; and acid addition and quaternary ammonium salts thereof. These compounds may be prepared by transesterification of the corresponding methyl or ethyl esters (R= OH) with 3- quinuclidinol; or by reacting the corresponding acid chlorides (R#OH) with 3-quinuclidinol (or e.g. its Na salt). Therapeutic compositions for oral, parenteral or rectal administration, comprise compounds of the above formula, which are stated to be useful where atropine antispasmodics and central anticholinergic agents are indicated.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.